Effects of protriptyline: A Synthesis of Findings from 24 Studies

  1. Home
  2. Effects of protriptyline
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of protriptyline: A Synthesis of Findings from 24 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of protriptyline: A Synthesis of Findings from 24 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Main research findings

Several studies have shown that prasugrel has a more potent and rapid antiplatelet effect compared to high-dose clopidogrel and other antiplatelet drugs. 3 、 5 、 11 、 20 、 22 These studies suggest that prasugrel may reduce the risk of ischemic events, but they also point to an increased risk of bleeding. 10 While prasugrel can potentially decrease ischemic events, it also carries the risk of increased bleeding, emphasizing the need for careful evaluation of individual patient risks and benefits. 10

Prasugrel’s antiplatelet effect may be influenced by the use of proton pump inhibitors like ticlopidine and lansoprazole. 4 The pharmacokinetics and pharmacodynamics of prasugrel can be altered by concurrent use of proton pump inhibitors, potentially requiring dose adjustments. 4 Prasugrel’s pharmacodynamics can be affected by concurrent use of aspirin, and the route of administration of aspirin can impact its effect. 16 The dosage of prasugrel can influence its effect, demonstrating dose-dependent inhibition of platelet aggregation. 2 、 23 、 16 Factors like age, weight, and CYP2C19 genotype may require adjustments in prasugrel dosage. 6 、 13

Prasugrel’s antiplatelet effect may vary depending on the patient’s build and drug metabolism capabilities. 6 、 13 After prasugrel administration, platelet function gradually recovers, and platelet function is largely restored to baseline within seven days of discontinuing prasugrel. 8 、 20

Benefits and risks

Benefits summary

Using prasugrel could potentially lower the risk of ischemic events. 5 、 20 Moreover, the antiplatelet effect of prasugrel has been shown to be more potent and rapid compared to high-dose clopidogrel and other antiplatelet drugs. 3 、 5 、 11 、 20 、 22 Further research is needed to evaluate the efficacy and safety of prasugrel. 20

Risks summary

The use of prasugrel might increase the risk of bleeding. 10 Prasugrel can potentially lead to a higher risk of bleeding compared to other antiplatelet medications. 10 、 20 The risk of bleeding associated with prasugrel can vary depending on factors like age, weight, and CYP2C19 genotype. 6 Using prasugrel could interact with other medications such as proton pump inhibitors and aspirin. 4 、 16 The pharmacokinetics and pharmacodynamics of prasugrel can be affected by concurrent use of proton pump inhibitors, potentially requiring dose adjustments. 4

Comparison across studies

Commonalities across studies

Many studies have shown that prasugrel has a more potent and rapid antiplatelet effect compared to high-dose clopidogrel and other antiplatelet drugs. 3 、 5 、 11 、 20 、 22 These studies also suggest that prasugrel use may reduce the risk of ischemic events. 5 、 20 However, these studies also highlight that prasugrel use can lead to an increased risk of bleeding. 10

Differences across studies

The studies show that the antiplatelet effect of prasugrel can vary based on the patient's build, drug metabolism capabilities, and other factors such as the patient's age and weight. 6 、 13 Prasugrel’s antiplatelet effect can be influenced by concurrent use of proton pump inhibitors such as ticlopidine and lansoprazole. 4 The pharmacodynamics of prasugrel can be affected by concurrent use of aspirin, and the route of administration of aspirin can impact its effect. 16

Consistency and contradictions in results

Many studies have shown that prasugrel has a more potent and rapid antiplatelet effect compared to high-dose clopidogrel and other antiplatelet drugs. 3 、 5 、 11 、 20 、 22 These studies also suggest that prasugrel use may reduce the risk of ischemic events. 5 、 20 However, these studies also highlight that prasugrel use can lead to an increased risk of bleeding. 10 The effectiveness of prasugrel can vary depending on the patient's build, drug metabolism capabilities, and other factors such as the patient's age and weight. 6 、 13 、 4 、 16 These studies indicate that while prasugrel can be effective, its use is associated with a potential increase in bleeding risk, and its effects may vary based on various factors.

Practical implications and considerations

The use of prasugrel can potentially reduce the risk of ischemic events. 5 、 20 However, the use of prasugrel can also increase the risk of bleeding. 10 It’s crucial to carefully weigh the risks and benefits for each patient before deciding to use prasugrel. 10 The risk of bleeding associated with prasugrel can vary depending on factors like age, weight, and CYP2C19 genotype. 6 Prasugrel can interact with other medications such as proton pump inhibitors and aspirin. 4 、 16 Therefore, these factors should be taken into account when considering prasugrel use.

Limitations of current research

These studies don’t uncover every aspect of prasugrel’s effects. Further research is necessary to understand the full impact of prasugrel, particularly considering its potential for varying effects based on individual factors like build, drug metabolism capabilities, and interactions with other medications. 6 、 13 、 4 、 16

Future research directions

Additional research is needed to explore prasugrel’s effects in greater detail. Specifically, research that considers factors like build, drug metabolism capabilities, and interactions with other medications, as these factors can influence prasugrel’s effectiveness. 6 、 13 、 4 、 16 Research evaluating the long-term effects and safety of prasugrel is also essential. 20

Conclusion

While prasugrel can potentially reduce the risk of ischemic events, it also carries the risk of increased bleeding. 10 When considering prasugrel use, it is vital to consider these factors. Further research is necessary to understand the complete impact of prasugrel, especially in relation to its potential variations based on individual characteristics like build, drug metabolism capabilities, and interactions with other medications. 6 、 13 、 4 、 16

Literature analysis of 24 papers
Positive Content
21
Neutral Content
2
Negative Content
1
Article Type
22
1
2
2
24
1.

The platelet inhibitory effects and pharmacokinetics of prasugrel after administration of loading and maintenance doses in healthy subjects.

Author: JakubowskiJoseph A, PayneChristopher D, BrandtJohn T, WeerakkodyGovinda J, FaridNagy A, SmallDavid S, NaganumaHideo, LiGrace Ying, WintersKenneth J

Rapid and sustained inhibition
Well tolerated

Prasugrel, a novel thienopyridine, rapidly and consistently inhibited platelet aggregation after oral administration of a loading dose and maintained inhibition with once-daily maintenance dosing. Prasugrel was well-tolerated in healthy subjects.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

2.

Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects.

Author: JakubowskiJoseph A, PayneChristopher D, WeerakkodyGovinda J, BrandtJohn T, FaridNagy A, LiYing G, NaganumaHideo, LachnoD Richard, WintersKenneth J

Platelet inhibition

This study assessed the interaction of prasugrel, an orally active antiplatelet agent, with aspirin in healthy subjects. Prasugrel, dosed as LD followed by MD in the presence of ASA, was well tolerated and provided greater platelet inhibition than ASA alone.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

3.

Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.

Author: WiviottStephen D, TrenkDietmar, FrelingerAndrew L, O'DonoghueMichelle, NeumannFranz-Josef, MichelsonAlan D, AngiolilloDominick J, HodHanoch, MontalescotGilles, MillerDebra L, JakubowskiJoseph A, CairnsRichard, MurphySabina A, McCabeCarolyn H, AntmanElliott M, BraunwaldEugene,

Platelet aggregation inhibition

This study aims to evaluate the relative antiplatelet effects of prasugrel versus high-dose clopidogrel in percutaneous coronary intervention patients.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

4.

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.

Author: SmallDavid S, FaridNagy A, PayneChristopher D, WeerakkodyGovinda J, LiYing G, BrandtJohn T, SalazarDaniel E, WintersKenneth J

Lansoprazole, a medication used to treat heartburn, does not affect the effectiveness of prasugrel, a medication used to prevent blood clots. However, lansoprazole may slightly reduce the effectiveness of clopidogrel, another medication used to prevent blood clots.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

5.

Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.

Author: MontalescotGilles, SiderisGeorgios, CohenRemy, MeulemanCatherine, Bal dit SollierClaire, BarthélémyOlivier, HenryPatrick, LimPascal, BeyguiFarzin, ColletJean-Philippe, MarshallDebra, LuoJunxiang, PetitjeanHelene, DrouetLudovic

Greater platelet inhibition
Reduced ischemic events

Prasugrel 10 mg daily significantly inhibited platelet aggregation compared to clopidogrel 150 mg daily in patients with acute coronary syndrome who had received a clopidogrel 900 mg loading dose.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel.

Author: ParodiGuido, BellandiBenedetta, VendittiFrancesco, CarrabbaNazario, ValentiRenato, MiglioriniAngela, GrasselliniSilvia, RamazzottiErica, AntoniucciDavid

Improved heart health
Bleeding
Stent thrombosis

This study evaluated the bleeding rates and adherence to treatment in patients treated with prasugrel, a medication used to prevent blood clots. The study found that bleeding rates in real-world patients were comparable to those reported in clinical trials, and that minimal bleeding events did not appear to affect adherence to treatment.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

Pharmacodynamic effects of prasugrel dosing regimens in patients on maintenance prasugrel therapy: results of a prospective randomized study.

Author: Tello-MontoliuAntonio, TomaselloSalvatore D, FerreiroJosé Luis, UenoMasafumi, SeecheranNaveen, DesaiBhaloo, KodaliMurali, CharltonRonald K, BoxLyndon C, ZenniMartin M, GuzmanLuis A, BassTheodore A, AngiolilloDominick J

Faster and higher platelet inhibition

A 60 mg dose of prasugrel was associated with faster and higher platelet inhibition compared with lower doses (10 mg and 30 mg) in patients on maintenance prasugrel therapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

8.

Recovery of platelet function after discontinuation of prasugrel or clopidogrel maintenance dosing in aspirin-treated patients with stable coronary disease: the recovery trial.

Author: PriceMatthew J, WalderJames S, BakerBrian A, HeiselmanDarell E, JakubowskiJoseph A, LoganDouglas K, WintersKenneth J, LiWei, AngiolilloDominick J

Consistent guidelines
Delayed recovery

The offset of prasugrel was consistent with current guidelines regarding the recommended waiting period for surgery after discontinuation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

9.

Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.

Author: AlexopoulosDimitrios, XanthopoulouIoanna, GkizasVassilios, KassimisGeorge, TheodoropoulosKonstantinos C, MakrisGeorge, KoutsogiannisNikolaos, DamelouAnastasia, TsigkasGrigorios, DavlourosPeriklis, HahalisGeorge

ST-elevation MI treatment

Ticagrelor and prasugrel, both strong platelet inhibitors, exhibited an initial delay in the onset of their antiplatelet action in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Ticagrelor did not appear superior to prasugrel in reducing platelet reactivity during the first 24 hours.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel.

Author: SalisburyAdam C, WangKaijun, CohenDavid J, LiYan, JonesPhilip G, SpertusJohn A

Reduced ischemic complications
Increased bleeding

This study developed predictive models to identify patients who would benefit most from prasugrel treatment for acute coronary syndrome, balancing the risks of bleeding and benefits of reduced ischemic events.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis.

Author: ChatterjeeSaurav, GhoseAbhimanyu, SharmaAbhishek, GuhaGunjan, MukherjeeDebabrata, FrankelRobert

Reduced ischemic events
Reduced mortality
Reduced stent thrombosis
Increased bleeding

This systematic review compared the clinical efficacy of prasugrel and ticagrelor with clopidogrel in patients with acute coronary syndrome.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

12.

Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial.

Author: LeeDong-Hyun, KimMoo Hyun, ParkTae-Ho, ParkJong Sung, ParkKyungil, ZhangHong-Zhe, SeoJeong-Min, LeeMichael S

HPR reduction

Prasugrel reloading is hypothesized to be more effective than clopidogrel reloading in patients with high on-treatment platelet reactivity (HPR) after an initial loading dose of clopidogrel.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

13.

Pharmacokinetic and pharmacodynamic effects of prasugrel in healthy Korean males.

Author: YuKyung-Sang, ParkKyung Woo, KellyRonan P, GuNamyi, PayneChristopher, SmallDavid S, ChoiHyunah C, KawakatsuEiji, PintonPhilippe

Acute coronary syndromes treatment

This study investigates the pharmacokinetics of prasugrel's active metabolite (R-138727) in healthy Korean males. The study found that prasugrel was well tolerated and that dosing strategies approved for white patients with acute coronary syndromes may be applicable to Asian patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

14.

Pharmacodynamic evaluation of switching from ticagrelor to prasugrel in patients with stable coronary artery disease: Results of the SWAP-2 Study (Switching Anti Platelet-2).

Author: AngiolilloDominick J, CurzenNicholas, GurbelPaul, VaitkusPaul, LipkinFred, LiWei, JakubowskiJoseph A, ZettlerMarjorie, EffronMark B, TrenkDietmar

Increased platelet reactivity
Switching medications risky

Switching from ticagrelor to prasugrel therapy was associated with an increase in platelet reactivity, which was partially mitigated by the administration of a loading dose.

Clinical Trial, Phase IVPost-marketing surveillance. Monitors long-term safety/efficacy after approval.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

15.

Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.

Author: RolliniFabiana, FranchiFrancesco, Tello-MontoliuAntonio, PatelRonakkumar, DarlingtonAndrew, FerreiroJosé Luis, ChoJung Rae, Muñiz-LozanoAna, DesaiBhaloo, ZenniMartin M, GuzmanLuis A, BassTheodore A, AngiolilloDominick J

Increased platelet inhibition

Cangrelor, an intravenous P2Y12 receptor inhibitor, is associated with further platelet P2Y12 receptor inhibitory effects in patients on maintenance prasugrel therapy exposed to a reloading dose of prasugrel.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

16.

Impact of Intravenous Lysine Acetylsalicylate Versus Oral Aspirin on Prasugrel-Inhibited Platelets: Results of a Prospective, Randomized, Crossover Study (the ECCLIPSE Trial).

Author: VivasDavid, MartínAgustín, BernardoEsther, Ortega-PozziMaría Aranzazu, TiradoGabriela, FernándezCristina, VilacostaIsidre, Núñez-GilIván, MacayaCarlos, Fernández-OrtizAntonio

Faster cyclooxygenase inhibition

Prasugrel and ticagrelor are new P2Y12-adenosine diphosphate receptor antagonists that are more effective than clopidogrel in reducing cardiovascular events in patients with an acute coronary syndrome. This study investigated the effects of achieving faster and stronger cyclooxygenase inhibition with intravenous lysine acetylsalicylate (LA) compared with oral aspirin on prasugrel-inhibited platelets.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

17.

A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study.

Author: RolliniFabiana, FranchiFrancesco, ChoJung Rae, DeGroatChristopher, BhattiMona, Muniz-LozanoAna, SinghKamaldeep, FerranteElisabetta, WilsonRyan E, DunnElizabeth C, ZenniMartin M, GuzmanLuis A, BassTheodore A, AngiolilloDominick J

Prasugrel and ticagrelor have different pharmacodynamic effects after switching from clopidogrel therapy, with prasugrel showing greater inhibition of platelet aggregation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

18.

Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.

Author: RolliniFabiana, FranchiFrancesco, HuJenny, KuretiMegha, AggarwalNiti, DurairajAshwin, ParkYongwhi, SeawellMichael, Cox-AlomarPedro, ZenniMartin M, GuzmanLuis A, SuryadevaraSiva, AntounPatrick, BassTheodore A, AngiolilloDominick J

Improved PK/PD profiles

This study aimed to investigate the pharmacokinetics and pharmacodynamics of crushing prasugrel tablets in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

20.

The role of prasugrel in the management of acute coronary syndromes: a systematic review.

Author: SpartalisM, TzatzakiE, SpartalisE, DamaskosC, AthanasiouA, MorisD, PolitouM

ACS management

This study systematically reviewed the current evidence regarding the role of prasugrel in the management of acute coronary syndrome (ACS).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

21.

Switching from clopidogrel to prasugrel to protect early invasive treatment in acute coronary syndromes: Results of the switch over trial.

Author: OttaniFilippo, FemiaEti Alessandra, CattaneoMarco, CaravitaLuciano, AttanasioChiara, GalvaniMarcello

Improved outcome
Improved platelet inhibition

Prasugrel provides better platelet inhibition than clopidogrel for patients with non-ST elevation acute coronary syndromes (NSTE-ACS) and has improved outcomes. However, switching from clopidogrel at the time of percutaneous coronary intervention (PCI) requires further study.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

22.

Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study.

Author: AriottiSara, Ortega-PazLuis, van LeeuwenMaarten, BrugalettaSalvatore, LeonardiSergio, AkkerhuisK Martijn, RimoldiStefano F, JanssensGladys, GianniUmberto, van den BergeJan C, KaragiannisAlexios, WindeckerStephan, ValgimigliMarco,

Off-target effects

Ticagrelor did not improve endothelial function or increase systemic adenosine plasma levels in stabilized patients who suffered from an acute coronary syndrome, compared to prasugrel and clopidogrel.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

23.

Pharmacodynamic assessment of prasugrel and clopidogrel in patients with non-cardioembolic stroke: a multicenter, randomized, active-control clinical trial.

Author: YamaguchiTakenori, ShiraiToshiaki, YoshibaSatoshi, AbeKenji, IkedaYasuo

antiplatelet effects
well tolerated
CYP2C19 polymorphisms

This multicenter randomized active-control comparative study investigated the dose-response antiplatelet effects of prasugrel compared with clopidogrel in Japanese patients with non-cardioembolic stroke.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

24.

COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial.

Author: VlachojannisGeorgios J, VogelRosanne F, WilschutJeroen M, LemmertMiguel E, DelewiRonak, DilettiRoberto, van VlietRia, van der WaardenNancy, NuisRutger-Jan, ParadiesValeria, AlexopoulosDimitrios, ZijlstraFelix, MontalescotGilles, AngiolilloDominick J, KrucoffMitchell W, Van MieghemNicolas M, SmitsPieter C

Platelet inhibition

Dual antiplatelet therapy is crucial for patients with ST elevation myocardial infarction (STEMI). This review discusses the evidence suggesting that administration of crushed tablets of the P2Y<sub>12</sub> inhibitor prasugrel improves drug absorption and achieves earlier antiplatelet effects in STEMI patients undergoing primary percutaneous coronary intervention (PCI).

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.